Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study

  1. the TOCICOV-study group
  2. Belén Ruiz-Antorán
  3. Aránzazu Sancho-López
  4. Ferrán Torres
  5. Víctor Moreno-Torres
  6. Itziar de Pablo-López
  7. Paulina García-López
  8. Francisco Abad-Santos
  9. Clara M. Rosso-Fernández
  10. Ana Aldea-Perona
  11. Eva Montané
  12. Ruth M. Aparicio-Hernández
  13. Roser Llop-Rius
  14. Consuelo Pedrós
  15. Paloma Gijón
  16. Carolina Hernández-Carballo
  17. María J. Pedrosa-Martínez
  18. Consuelo Rodríguez-Jiménez
  19. Guillermo Prada-Ramallal
  20. Lourdes Cabrera-García
  21. Josefa A. Aguilar-García
  22. Rocío Sanjuan-Jimenez
  23. Evelyn I. Ortiz-Barraza
  24. Enrique Sánchez-Chica
  25. Ana Fernández-Cruz

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1007/s40121-020-00373-8
  2. ScreenIT

    SciScore for 10.1101/2020.09.07.20189357: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    RandomizationAdditional studies, in particular randomized controlled studies, are needed to confirm these results and to figure out the characteristics of patients who benefit more from tocilizumab treatment.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    The software SPSS v.25 (IBM Corp., Armonk, NY) and SAS v9.4 (Cary, NC, USA) were used.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.09.07.20189357 on medRxiv